



# NCTN Brain Cancer Trials Portfolio (Open as of 9/15/2023)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



## Cross-disease trials:



## NCTN Brain Cancer Trials (Open as of 9/15/2023)

| Protocol Number  | Phase | Protocol Title  |
|------------------|-------|---|
| <b>A071401</b>   | II    | Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations  |
| <b>A071601</b>   | II    | Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas   |
| <b>A071701</b>   | II    | Genomically-Guided Treatment Trial in Brain Metastases  |
| <b>A071702</b>   | II    | A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatic Hypermutated Recurrent Glioblastoma  |
| <b>ACNS2021</b>  | II    | A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor  |
| <b>CCTG CE.7</b> | III   | A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases  |
| <b>N0577</b>     | III   | N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma                      |
| <b>NRG-BN003</b> | III   | Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma  |
| <b>NRG-BN005</b> | II    | A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas   |
| <b>NRG-BN009</b> | III   | Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brain Metastasis Velocity $\geq 4$ Brain Metastases/Year |
| <b>NRG-BN010</b> | II    | A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma                    |
| <b>NRG-BN011</b> | III   | A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma   |
| <b>NRG-BN012</b> | III   | A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases   |
| <b>S2000</b>     | II    | A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases  |
| <b>EAY191</b>    | Other | Molecular Analysis for Combination Therapy Choice (ComboMATCH)  |
| <b>EAY191-E4</b> | II    | Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial   |
| <b>EAY191-S3</b> | II    | Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial   |